Press releases //

Laboratoire CERBA signs licensing agreement with IntegraGen to commercialize miR-31-3p tumor expression test

IntegraGen SA and Laboratoire CERBA announced the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide  a test based on IntegraGen’s proprietary miR-31-3p biomarker to prescribing clinicians in France, Benelux, Middle East and Africa. Laboratoire CERBA will develop this test to complement its existing portfolio (…)  » 

News //

IntegraGen’s Scientific Advisory Board Meets to Review latest miR-31-3p data

IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…)  »